Therapy-induced enrichment of putative lung cancer stem-like cells.
about
The new concepts on overcoming drug resistance in lung cancer.Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung CancerPredictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.Side population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance.Genetic changes of non-small cell lung cancer under neoadjuvant therapyTargeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy.Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.Cancer stem cells: are they responsible for treatment failure?Roles of the Hippo pathway in lung development and tumorigenesis.Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.[Role of Hippo Signaling Pathway in Lung Cancer].Special Issue: New Approaches to Counteract Drug Resistance in Cancer.Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
P2860
Q33754114-230E3EAA-A853-429B-B36F-2A78A2FDD805Q33761564-9133B38D-6D59-4827-BC53-6DB15556A7B3Q34296534-A2C918AD-3604-4591-81F5-94A7DC8C6712Q35744111-979B009A-EA87-4D24-98A2-3D6AF0E573C8Q36619000-9ADB88EA-AD46-415A-8DFF-1A080E101151Q37287419-8CB017F2-AAA9-4F71-A8BC-273DCE502A56Q37301932-0737713D-113F-44F5-8123-EFC645DC38A1Q37615744-974ED93E-2961-415C-BCFB-CDB269B0378CQ37645066-A61D64B2-E63F-4E58-A4A5-83FF7B55EF7BQ38268164-81EAF401-83E0-4126-B2E4-E84C948A2DFFQ38341378-5DE40E98-CEFD-48D0-A745-BF5CDD5A1DDFQ38816754-7A7009FD-9265-4277-A8AB-9722FB50A122Q38893170-1A6B6B4F-C99E-4A16-9A1A-3788EEE22B22Q41593141-905AF586-197A-4500-99BB-66992D3A4A55Q41615232-C9FFC497-A024-4B98-AFE2-CD4599E02D98Q41631094-6E7A4794-C329-47C5-9CD1-179147CF5518Q41866323-A8974DFC-2FE9-4486-B32E-DD3D6ABD01B7Q49958922-03F6C1FB-AF02-4A33-9C42-CE46D9F05C9DQ51234018-84BF1C52-63CA-499B-874B-C0EA63221A01Q53811526-99052B91-9695-445E-A606-8B5A08ACF1AA
P2860
Therapy-induced enrichment of putative lung cancer stem-like cells.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapy-induced enrichment of putative lung cancer stem-like cells.
@en
type
label
Therapy-induced enrichment of putative lung cancer stem-like cells.
@en
prefLabel
Therapy-induced enrichment of putative lung cancer stem-like cells.
@en
P2860
P50
P356
P1476
Therapy-induced enrichment of putative lung cancer stem-like cells
@en
P2093
M Helena Vasconcelos
P2860
P304
P356
10.1002/IJC.28478
P577
2013-10-21T00:00:00Z